{"title":"同期放化疗对单侧或双侧参数侵犯的IIB期宫颈癌患者预后的影响","authors":"Xi-Lin Yang, Li-Chun Wei, Jian-Li He, Tie-Jun Wang, Li Ran, Li-Juan Zou, Xiao-Ge Sun, Xiao-Mei Li, Zi Liu, Yong-Gang Shi, Sha Li, Feng-Ju Zhao, Kun Gao, Wei Zhong, Guang-Hui Cheng, Ya-Li Gao, Bao-Sheng Sun, Jun-Fang Yan, Fu-Quan Zhang","doi":"10.1093/oncolo/oyaf329","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To compare the survival difference between 2018 International Federation of Gynecology and Obsterics (FIGO) stage IIB cervical cancer (CC) patients with Unilateral parametrial invasion (UL) and Bilateral parametrial invasion (BL) disease and explore the significant role of parametrial invasion (PI) in prognosis prediction.</p><p><strong>Methods: </strong>A total of 506 stage IIB CC patients were identified from the multi-center study and patients were divided into UL and BL groups according to gynecological and radiological examination. Survival outcomes were estimated and compared between two groups before and after Propensity Scoring Matching (PSM). The role of upper 2/3 vaginal invasion (VI) in impacting survival probability was also assessed. The random forest (RF) model was constructed and validated to select important features related to survival outcomes and predict prognosis for these patients. The SHapley Additive exPlanation (SHAP) was further introduced to provide better understanding towards the findings from RF model.</p><p><strong>Results: </strong>Significant better 5-year overall survival (OS) was observed among patients with UL disease whether before [BL : 61.7% (95%CI : 57.0%-66.4%); UL : 84.8% (95%CI : 82.4%-87.2%); HR = 2.83, 95%CI : 1.90-4.20, P < 0.001] or after PSM [BL : 61.3% (95%CI : 56.6%-66.0%); UL : 81.2% (95%CI : 77.3%-85.1%); HR = 2.51, 95%CI : 1.56-4.04, P < 0.001]. Similar findings could also be observed in terms of progression free survival (PFS). The presence of VI didn't significantly impair the survival probability whether in UL or BL group (All P > 0.05). RF model was constructed, which possessed decent predictive ability both in the training (AUC = 0.893; 95%CI : 0.874-0.912) and validation cohort (AUC = 0.879; 95%CI : 0.801-0.957). PI was identified to be the paramount feature in affecting the survival outcomes for stage IIB CC patients through the Beeswarm summary plot and bar chart in SHAP analysis.</p><p><strong>Conclusion: </strong>Our findings demonstrated that 2018 FIGO stage IIB CC patients with BL disease had worse prognosis than those with UL disease and PI was the most significant feature in prognosis prediction for these patients.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Different prognosis for stage IIB cervical cancer patients with unilateral or bilateral parametrial invasion treated with concurrent chemoradiotherapy.\",\"authors\":\"Xi-Lin Yang, Li-Chun Wei, Jian-Li He, Tie-Jun Wang, Li Ran, Li-Juan Zou, Xiao-Ge Sun, Xiao-Mei Li, Zi Liu, Yong-Gang Shi, Sha Li, Feng-Ju Zhao, Kun Gao, Wei Zhong, Guang-Hui Cheng, Ya-Li Gao, Bao-Sheng Sun, Jun-Fang Yan, Fu-Quan Zhang\",\"doi\":\"10.1093/oncolo/oyaf329\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To compare the survival difference between 2018 International Federation of Gynecology and Obsterics (FIGO) stage IIB cervical cancer (CC) patients with Unilateral parametrial invasion (UL) and Bilateral parametrial invasion (BL) disease and explore the significant role of parametrial invasion (PI) in prognosis prediction.</p><p><strong>Methods: </strong>A total of 506 stage IIB CC patients were identified from the multi-center study and patients were divided into UL and BL groups according to gynecological and radiological examination. Survival outcomes were estimated and compared between two groups before and after Propensity Scoring Matching (PSM). The role of upper 2/3 vaginal invasion (VI) in impacting survival probability was also assessed. The random forest (RF) model was constructed and validated to select important features related to survival outcomes and predict prognosis for these patients. The SHapley Additive exPlanation (SHAP) was further introduced to provide better understanding towards the findings from RF model.</p><p><strong>Results: </strong>Significant better 5-year overall survival (OS) was observed among patients with UL disease whether before [BL : 61.7% (95%CI : 57.0%-66.4%); UL : 84.8% (95%CI : 82.4%-87.2%); HR = 2.83, 95%CI : 1.90-4.20, P < 0.001] or after PSM [BL : 61.3% (95%CI : 56.6%-66.0%); UL : 81.2% (95%CI : 77.3%-85.1%); HR = 2.51, 95%CI : 1.56-4.04, P < 0.001]. Similar findings could also be observed in terms of progression free survival (PFS). The presence of VI didn't significantly impair the survival probability whether in UL or BL group (All P > 0.05). RF model was constructed, which possessed decent predictive ability both in the training (AUC = 0.893; 95%CI : 0.874-0.912) and validation cohort (AUC = 0.879; 95%CI : 0.801-0.957). PI was identified to be the paramount feature in affecting the survival outcomes for stage IIB CC patients through the Beeswarm summary plot and bar chart in SHAP analysis.</p><p><strong>Conclusion: </strong>Our findings demonstrated that 2018 FIGO stage IIB CC patients with BL disease had worse prognosis than those with UL disease and PI was the most significant feature in prognosis prediction for these patients.</p>\",\"PeriodicalId\":54686,\"journal\":{\"name\":\"Oncologist\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-10-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncologist\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/oncolo/oyaf329\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyaf329","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Different prognosis for stage IIB cervical cancer patients with unilateral or bilateral parametrial invasion treated with concurrent chemoradiotherapy.
Objective: To compare the survival difference between 2018 International Federation of Gynecology and Obsterics (FIGO) stage IIB cervical cancer (CC) patients with Unilateral parametrial invasion (UL) and Bilateral parametrial invasion (BL) disease and explore the significant role of parametrial invasion (PI) in prognosis prediction.
Methods: A total of 506 stage IIB CC patients were identified from the multi-center study and patients were divided into UL and BL groups according to gynecological and radiological examination. Survival outcomes were estimated and compared between two groups before and after Propensity Scoring Matching (PSM). The role of upper 2/3 vaginal invasion (VI) in impacting survival probability was also assessed. The random forest (RF) model was constructed and validated to select important features related to survival outcomes and predict prognosis for these patients. The SHapley Additive exPlanation (SHAP) was further introduced to provide better understanding towards the findings from RF model.
Results: Significant better 5-year overall survival (OS) was observed among patients with UL disease whether before [BL : 61.7% (95%CI : 57.0%-66.4%); UL : 84.8% (95%CI : 82.4%-87.2%); HR = 2.83, 95%CI : 1.90-4.20, P < 0.001] or after PSM [BL : 61.3% (95%CI : 56.6%-66.0%); UL : 81.2% (95%CI : 77.3%-85.1%); HR = 2.51, 95%CI : 1.56-4.04, P < 0.001]. Similar findings could also be observed in terms of progression free survival (PFS). The presence of VI didn't significantly impair the survival probability whether in UL or BL group (All P > 0.05). RF model was constructed, which possessed decent predictive ability both in the training (AUC = 0.893; 95%CI : 0.874-0.912) and validation cohort (AUC = 0.879; 95%CI : 0.801-0.957). PI was identified to be the paramount feature in affecting the survival outcomes for stage IIB CC patients through the Beeswarm summary plot and bar chart in SHAP analysis.
Conclusion: Our findings demonstrated that 2018 FIGO stage IIB CC patients with BL disease had worse prognosis than those with UL disease and PI was the most significant feature in prognosis prediction for these patients.
期刊介绍:
The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.